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Abstract: An 18-year-old obese man with a body mass index of 40, diagnosed with 
attention-deﬁ  cit hyperactivity disorder and treated with methylphenidate (Concerta®) was acutely 
admitted to hospital with hypoxia and dyspnoea. On investigation signs of liver-, renal-, and 
heart-failure were found. Noradrenalin infusion was started. Echocardiography showed dilated 
left ventricle and an ejection fraction (EF) of 25%. Liver function improved, noradrenalin and 
dobutamine were tapered, but three days after admission a new echocardiography showed an 
EF of 10%. The patient was transferred to the National Hospital (Rikshospitalet, Oslo), where 
intensiﬁ  ed treatment including intra aortic balloon pump (IABP) was instituted. Cardiac function 
improved, and 3 weeks later the IABP was disconnected. EF at this point was 15%. The patient 
was denied heart transplantation due to various cofactors. The investigation concluded with a 
probable relationship between his cardiomyopathy and the use of methylphenidate (Concerta).
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Heart failure due to idiopathic dilated cardiomyopathy (DCM) is rare in young 
people. Familial linkage is often found (Seidman and Seidman 2001), and various 
drugs, especially cytotoxic drugs, may cause cardiomyopathy (Giordano et al 2002). 
Cocaine and amphetamines are known to have caused DCM (Lange and Hillis 2001). 
There are very few reports linking methylphenidate therapy to DCM, but recently the 
Journal of the Norwegian Medical Association described how a young boy treated 
with methylphenidate died of dilated cardiomyopathy (Tollofsrud and Hoel 2006). 
We report a similar case but with a different outcome.
Case description
An 18-year-old male was diagnosed with attention-deﬁ  cit hyperactivity disorder 
(ADHD) in 2005. He was overweight with a body mass index (BMI) of 40. He was 
started on quetiapine fumarate (Seroquel®) 900 mg daily in April 2005 and methylphe-
nidate (Concerta®) 54 mg daily in September 2005. In the beginning of August 2006 
he was admitted to his local hospital with severe dyspnoea, tachypnea, tachycardia, 
and cyanosis. On admission the blood pressure was 120/80 mmHg, and the arterial 
blood gas revealed a pH of 7.45, pCO2 of 3.55 kPa, paO2 of 7.76 kPa, and BE of −5.1 
mmol/l. C-reactive protein was not elevated. The chest X-ray showed an enlarged heart. 
He developed hemoptysis and was treated with unfractionated heparin in suspicion of 
pulmonary embolism. He subsequently developed cardiogenic shock and was treated 
with vasoactive drugs. In spite of the treatment he became oliguric and his liver enzymes 
were rising. He was referred to our hospital for further treatment. On admission the 
blood pressure was 90/60 mmHg, despite infusion with noradrenaline. His heart rate 
was 130/minute and his temperature was 38.4 °C. A thoracic computed tomography 
scan did not show pulmonary embolism. Echocardiography revealed biventricular Vascular Health and Risk Management 2008:4(2) 478
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failure and left ventricular end diastolic diameter was 7 cm. 
The left ventricle was severely hypokinetic with an ejection 
fraction (EF) of 20%–25%. The left ventricular end diastolic 
pressure was markedly elevated, and there was a moderate 
mitral regurgitation. Intermittent hemodialysis was initiated. 
His liver function improved slightly, but despite dialysis 
the renal function deteriorated with increasing creatinine 
values. After three days there was a further worsening of 
the left ventricular systolic function with an ejection frac-
tion of 10%–12% and marked pulmonary hypertension 
with systolic pulmonary pressure estimated to 30 mmHg. 
The clinical picture resembled dilated cardiomyopathy with 
low output failure causing renal and liver failure. We sus-
pected drug-induced cardiomyopathy and methylphenidate 
and quetiapine fumarate were discontinued. Screening for 
infectious pathogens, immunological markers, and iron or 
amyloid deposition were all negative. After three days he 
was transferred to the National Hospital (Rikshospitalet, 
Oslo) with ongoing noradrenaline and dobutamine infusions. 
Shortly after admission an intraaortic balloon pump (IABP) 
was inserted and noradrenaline was replaced by nitroprusside. 
Coronary angiography was normal. Endomyocardial biopsy 
from the right ventricle did not reveal any distinct myocardial 
pathology. On treatment with IABP, nitroprusside, and dialy-
sis, the clinical situation gradually improved and the liver 
function returned to normal. His renal function also improved 
with increasing diuresis and creatinine fell from 798 to 98 
µmol/l. His EF was still markedly reduced (15%). Because 
of behavioral problems and adipose stature, he was denied a 
heart transplant. He was treated with IABP for 26 days, and 
after 28 days he was transferred back to our hospital. At that 
time his liver and renal functions were normal. He was treated 
with an angiotensin-converting enzyme (ACE)-inhibitor, 
a beta-blocker, and diuretics. During the following two 
weeks his clinical status improved and he was subsequently 
discharged to his home. The echocardiography still showed 
markedly dilated left ventricle with EF of 20%.
In March 2007, his clinical status was improved and he 
was in function class II (New York Heart Association) with 
an EF estimated by echocardiography to 30%–35%.
Discussion
Our patient presented with progressive cardiac failure leading 
to liver and renal failure. Previously he was diagnosed with 
ADHD and was treated with methylphenidate and quetiapine 
fumarate. The Journal of the Norwegian Medical Associa-
tion recently presented a case describing a 17-year-old boy 
who died from dilated cardiomyopathy. Treatment with 
methylphenidate (Ritalin®) for 10 years was suspected to be 
the cause (Tollofsrud and Hoel 2006).
Cardiac adverse effects from methylphenidate have been 
shown to affect myocardial ultra-structure in rats. This effect 
was irreversible after 12 weeks (Henderson and Fischer 1995). 
Methylphenidate is a drug with central nervous stimulating 
action and with similar effects as amphetamines. Both increase 
synaptic and intracellular dopamine in rodents and baboons 
(Schiffer et al 2006). For amphetamine the mechanism 
has been shown to be both increased release of catecholamines 
and a blockade of their synaptic reuptake and degradation 
(Knepper et al 1988). It is the increase in adrenergic action 
that is believed to be cardiotoxic over time and promote 
cardiomyopathy (Lange and Hillis 2001). Thus, in transgenic 
mice, myocardial overexpression of beta-adrenergic receptors 
was associated with myocyte apoptosis and the development 
of dilated cardiomyopathy (Singh et al 2001).
With a BMI of 40 our patient had extreme obesity. The 
hyperdynamic circulation, with increased cardiac output, 
thought to be a compensatory adaptation to increased adipose 
tissue may, at the expense of left ventricular hypertrophy and 
remodeling, lead to nonischemic dilated cardiomyopathy 
in severe obese subjects (McGavock et al 2006). This is, 
however, unlikely as the only cause in our young patient. 
Human obesity is also characterized by sympathetic nervous 
activation (Eikelis and Esler 2005). A possible obesity-linked 
susceptibility to the toxic effect of methylphenidate could 
therefore play a role in the development of DCM in our 
patient, especially with regards to the short treatment time 
of one year. In comparison, the previously reported patient 
had been treated with the same drug for 10 years (Tollofsrud 
and Hoel 2006).
There is one report of myocarditis associated with que-
tiapine (Roesch-Ely 2002), and our patient had been treated 
with quetiapine for 17 months when he was admitted to 
our hospital. This drug could therefore also play a role in 
the development of DCM. There was, however, no signs of 
myocarditis or any other distinct pathology on myocardial 
biopsy.
In February 2006, an advisory committee to the U.S. 
Food and Drug Administration (FDA) urged the most seri-
ous FDA warning, the “black box”, be placed on all drugs 
prescribed to treat ADHD (Nissen 2006). The concern, 
however, was not restricted to cardiomyopathy alone, but 
to various cardiovascular side effects. After this report, the 
Norwegian and European Medicines Agency also pay close 
attention to reports on cardiovascular side effects of these 
drugs (Madsen 2006).Vascular Health and Risk Management 2008:4(2) 479
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Conclusion
We report the second case in a short time in Norway of 
serious cardiomyopathy in young patients treated with 
methylphenidate. The concern is that methylphenidate is 
the responsible agent. Although the number treated with 
this drug is high, and the reported cardiovascular side effects 
are few, we are concerned about the serious inﬂ  iction this 
side effect could have on children and young adults. To our 
knowledge, there are no guidelines regarding how to identify 
individuals prone to develop cardiomyopathy due to central 
stimulating drugs. Further studies addressing this problem 
need to be done.
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